Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ureter

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    74 result(s) found for: Ureter. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2020-004494-41 Sponsor Protocol Number: CLIN2001UCM301 Start Date*: 2021-11-11
    Sponsor Name:Steba biotech S.A.
    Full Title: Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low-Grade Upper Tract Urothelial Cancer
    Medical condition: Low Grade Upper Tract Urothelial Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077840 Urothelial cancer of renal pelvis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046375 Ureter cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) IT (Ongoing) AT (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005403-17 Sponsor Protocol Number: KH-MS-JAW-01 Start Date*: 2007-12-10
    Sponsor Name:GE Healthcare
    Full Title: A prospective, comparative single center study of Hexvix® fluorescence uretero-renoscopy and white light uretero-renoscopy in the detection of upper urinary tract urothelial cell carcinoma
    Medical condition: Upper urinary tract (ureters and pyela/renal pelvises) urothelial cell carcinoma for which blue light uretero-renoscopy and biopsies are performed for diagnosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026431 Malignant neoplasm of renal pelvis and ureter transitional cell regional LLT
    9.1 10038497 Renal pelvis and ureter transitional cell cancer localized LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007591-42 Sponsor Protocol Number: SPON416-07(WCTU011) Start Date*: 2009-01-14
    Sponsor Name:Cardiff University
    Full Title: A Phase II single-arm trial to evaluate cisplatin and gemcitabine chemotherapy in combination with sunitinib for first-line treatment of patients with advancd transitional carcinoma of the urothelium.
    Medical condition: Advanced transitional cell carcinoma of the urothelium.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005003 Bladder cancer LLT
    9.1 10038517 Renal pelvis cancer NOS LLT
    9.1 10046375 Ureter cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-002577-33 Sponsor Protocol Number: ICR-CTSU/2011/10031 Start Date*: 2012-01-04
    Sponsor Name:Institute of Cancer Research
    Full Title: A Phase III randomised trial of Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer
    Medical condition: Upper urinary tract transitional cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044407 Transitional cell cancer of the renal pelvis and ureter PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-004857-33 Sponsor Protocol Number: 0416-ASG Start Date*: 2017-06-01
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma
    Medical condition: subjects in untreated (1st line)* and platinum-based pretreated (2nd and 3rd line) subjects with metastatic or surgically unresectable TCC *First-line has been finally stopped since 06.01.2020
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038514 Renal pelvis and ureteric cancer transitional cell metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071664 Bladder transitional cell carcinoma metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038509 Renal pelvis and ureteric cancer metastatic transitional cell LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044423 Transitional cell carcinoma ureter metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044406 Transitional cell cancer of renal pelvis and ureter metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038498 Renal pelvis and ureter transitional cell cancer metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026427 Malignant neoplasm of renal pelvis and ureter localized transitional cell LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066752 Bladder transitional cell carcinoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026428 Malignant neoplasm of renal pelvis and ureter metastatic transitional cell LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026426 Malignant neoplasm of renal pelvis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044428 Transitional cell carcinoma urethra metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044419 Transitional cell carcinoma of the bladder stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071080 Transitional cell carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004628-39 Sponsor Protocol Number: ABACUS-2 Start Date*: 2020-12-16
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II study of neoadjuvant immune checkpoint inhibitors in urothelial cancer
    Medical condition: Tumours of the urothelial tract requiring surgery (T1 high grade-T4a of the bladder, rare histological subtypes) and upper urinary tract (high grade or high risk)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046384 Ureteral cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026426 Malignant neoplasm of renal pelvis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001527-39 Sponsor Protocol Number: SGN22E-002 Start Date*: 2021-02-16
    Sponsor Name:Seagen Inc.
    Full Title: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
    Medical condition: Urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046723 Urothelial carcinoma ureter LLT
    20.0 100000004864 10046728 Urothelial carcinoma urethra LLT
    21.1 100000004864 10077840 Urothelial cancer of renal pelvis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2022-000514-33 Sponsor Protocol Number: OZBS62.20366 Start Date*: 2022-10-10
    Sponsor Name:Erasmus MC
    Full Title: CHemotherapy And Sequential ImmunoTherapy for locally advanced urothelial cancer: the CHASIT study
    Medical condition: Urothelial cancer of the bladder, upper urinary tract or urethra.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046723 Urothelial carcinoma ureter LLT
    20.0 100000004864 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003498-27 Sponsor Protocol Number: JEVTCC-SOGUG-2011-04 Start Date*: 2011-12-19
    Sponsor Name:Grupo Español de Tratamiento de Tumores Genitourinarios (SOGUG)-Spanish Genitourinary Oncologic Group
    Full Title: A phase II open label study of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelium who have progressed ?12 months after a previous platinum based chemo...
    Medical condition: advanced or metastatic transitional cell carcinoma of the urothelium
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038498 Renal pelvis and ureter transitional cell cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001841-34 Sponsor Protocol Number: PLUTO2011 Start Date*: 2012-01-12
    Sponsor Name:NHS Greater Glasgow Health Board [...]
    1. NHS Greater Glasgow Health Board
    2. University of Glasgow
    Full Title: A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium.
    Medical condition: Relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044426 Transitional cell carcinoma urethra LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044420 Transitional cell carcinoma of the bladder stage unspecified LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044407 Transitional cell cancer of the renal pelvis and ureter PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007615-82 Sponsor Protocol Number: SPON417-07 Start Date*: 2009-09-16
    Sponsor Name:Cardiff University
    Full Title: A Phase I/II single-arm trial to evaluate the combination of cisplatin and gemcitabine with the mTOR inhibitor temsirolimus for treatment of advanced cancers, including first-line treatment of pati...
    Medical condition: Advanced cancers including transitional cell carcinoma of the urothelium
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038517 Renal pelvis cancer NOS LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046375 Ureter cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005983-12 Sponsor Protocol Number: INT01/12 Start Date*: 2012-03-21
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of the fully human monoclonal antibody against transforming growth factor-beta (TGF-beta) receptor ALK1 (PF-03446962) in relapsed or refractory urothelial cancer (UC) failing first-l...
    Medical condition: Relapsed or refractory urothelial cancer after failure of 1st line platinum-containing chemotherapy regimen for metastatic disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038502 Renal pelvis and ureter neoplasms malignant HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044410 Transitional cell cancer of the renal pelvis and ureter recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044412 Transitional cell carcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066750 Bladder transitional cell carcinoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006371-42 Sponsor Protocol Number: 16112021 Start Date*: 2022-02-15
    Sponsor Name:Hanna-Reeta Viljamaa
    Full Title: Lasten vesikoureteraalisen refluksin diagnosointi isotooppimiktiokystografia- ja kontrastiaine UÄ-tutkimuksilla
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10047371 Vesicoureteral reflux LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003625-17 Sponsor Protocol Number: CA209-275 Start Date*: 2015-01-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A phase II single arm clinical trial of nivolumab (BMS-936558) in subjects with metastatic or unresectable urothelial cancer who have progressed or recurred following treatment with a platinum agen...
    Medical condition: metastatic or unresectable urothelial cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046723 Urothelial carcinoma ureter LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) BE (Completed) SE (Completed) CZ (Completed) FI (Completed) PL (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-001167-23 Sponsor Protocol Number: IMMU-132-06 Start Date*: 2019-03-20
    Sponsor Name:Immunomedics, Inc.
    Full Title: A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
    Medical condition: Histologically documented locally advanced (tumor [T] 4b, any node [N]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract predominant
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10077840 Urothelial cancer of renal pelvis LLT
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046723 Urothelial carcinoma ureter LLT
    20.0 100000004864 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DE (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002417-35 Sponsor Protocol Number: NUCOGI-VINGEM Start Date*: 2013-09-10
    Sponsor Name:Department of Oncology, Karolinska University Hospital
    Full Title: A multicenter, randomized phase II trial of vinflunine/gemcitabine versus carboplatin /gemcitabine as first line treatment in patients with metastatic urothelial carcinoma unfit for cisplatin based...
    Medical condition: Locally advanced or Metastatic urothelial carcinoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    18.1 100000004864 10046723 Urothelial carcinoma ureter LLT
    18.1 100000004864 10046714 Urothelial carcinoma bladder LLT
    18.1 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    18.1 100000004864 10046725 Urothelial carcinoma ureter metastatic LLT
    18.1 100000004864 10046730 Urothelial carcinoma urethra metastatic LLT
    18.1 100000004864 10046728 Urothelial carcinoma urethra LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-003479-78 Sponsor Protocol Number: SGN22E-001 Start Date*: 2018-08-29
    Sponsor Name:Seattle Genetics Inc.
    Full Title: A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoin...
    Medical condition: Patients with locally advanced or metastatic urothelial cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    20.0 100000004864 10046723 Urothelial carcinoma ureter LLT
    20.0 100000004864 10046728 Urothelial carcinoma urethra LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    20.0 100000004864 10077056 Urothelial carcinoma recurrent LLT
    21.1 100000004864 10077840 Urothelial cancer of renal pelvis LLT
    21.0 100000004864 10046715 Urothelial carcinoma bladder recurrent LLT
    21.0 100000004864 10046721 Urothelial carcinoma bladder stage III LLT
    21.0 100000004864 10046722 Urothelial carcinoma bladder stage IV LLT
    21.0 100000004864 10046725 Urothelial carcinoma ureter metastatic LLT
    21.0 100000004864 10046726 Urothelial carcinoma ureter recurrent LLT
    21.0 100000004864 10046730 Urothelial carcinoma urethra metastatic LLT
    21.0 100000004864 10046731 Urothelial carcinoma urethra recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) IT (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2012-001924-37 Sponsor Protocol Number: HJU1 Start Date*: 2013-11-05
    Sponsor Name:Fredericia Hospital
    Full Title: Relaxation of the ureter during ureterorenoscopy
    Medical condition: Elevated pressure in the upper urinary tract during ureterorenoscopy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10023436 Kidney stone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004475-13 Sponsor Protocol Number: 13.031 Start Date*: 2014-03-05
    Sponsor Name:Fredericia Hospital
    Full Title: Pharmacological relaxation of the ureter when using access sheaths during ureterorenoscopy
    Medical condition: Resistance in the ureter when inserting a ureteral access sheath during ureterorenoscopy.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10023436 Kidney stone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-005241-36 Sponsor Protocol Number: Start Date*: 2005-06-21
    Sponsor Name:ACROSS Group
    Full Title: Phase II clinical trial of Cisplatin, Gemcitabine and Trastuzumab (Herceptin®) as first line treatment of advanced irresectable transitional-cell urothelial carcinoma with overexpression of C-erbB-2
    Medical condition: Advanced irresectable transitional-cell urothelial carcinoma, that includes cancer of the bladder, ureter and renal pelvis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 18 17:59:01 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA